FDA Grants Priority Review for Frontline Zanubrutinib Regimen
On November 4, BeOne disclosed FDA acceptance and Priority Review of a supplemental application for zanubrutinib plus rituximab in untreated mantle cell lymphoma. The application rests on MANGROVE, a 510-patient randomized Phase 3 trial…
